Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case–control study

BMC Cancer

Jeongseon Kim³  You Jin Lee²  Eun Kyung Lee²  Jeonghee Lee³  Aesun Shin¹  Sun-Young Kong⁴  Young Ae Cho³ 

[1]Department of Preventive Medicine, College of Medicine, Seoul National University, Seoul 110-799, Korea

[2]Center for Thyroid Cancer, National Cancer Center, Goyang-si 410-769, Gyeonggi-do, Korea

[3]Division of Cancer Epidemiology and Prevention, Molecular Epidemiology Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si 410-769, Gyeonggi-do, Korea

[4]Department of Laboratory Medicine, Center for Diagnostic Oncology, Hospital, National Cancer Center, Goyang-si 410-769, Gyeonggi-do, Korea

关键词: TPOAb;    Autoimmunity;    Thyroid function;    Biomarkers;    Thyroid cancer;   

Others  :  1118006
DOI  :  10.1186/1471-2407-14-873

 received in 2014-05-09, accepted in 2014-11-13,  发布年份 2014

【 摘 要 】

Background

A remarkable increase in the number of thyroid cancer cases has been reported in recent years; however, the markers to predict high-risk groups have not been fully established.

Methods

We conducted a case–control study (257 cases and 257 controls) that was nested in the Cancer Screenee Cohort Study between August 2002 and December 2010; the mean follow-up time for this study was 3.1 ± 2.2 years. The levels of total triiodothyronine (TT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), thyroglobulin (Tg), anti-thyroperoxidase antibody (TPOAb), and anti-thyroglobulin antibody (TgAb) were measured using samples with pre-diagnostic status. Logistic regression models were used to examine the association between thyroid function/autoimmunity and thyroid cancer risk.

Results

When the markers were categorized by the tertile distributions of the control group, the highest tertile of FT4 (OR = 1.73, 95% CI = 1.11 - 2.69) and the middle tertile of TSH (OR = 1.77, 95% CI = 1.14 - 2.74) were associated with an increased risk of thyroid cancer by multivariate analyses. In addition, an elevated risk for thyroid cancer was found in subjects with TPOAb levels above 30 IU/mL (OR = 8.47, 95% CI = 5.39 - 13.33 for 30–60 IU/mL and OR = 4.48, 95% CI = 2.59 - 7.76 for ≥60 IU/mL). Stratified analyses indicated that some of these associations differed by sex, BMI, smoking status, and the duration of follow-up.

Conclusions

This study demonstrated that the levels of biomarkers of thyroid function/autoimmunity, particularly the presence of TPOAb, might be used as diagnostic markers for predicting thyroid cancer risk. Our findings suggest that careful monitoring of thyroid biomarkers may be helpful for identifying Korean populations at high-risk for thyroid cancer.

【 授权许可】

   
2014 Cho et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R: Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013, 2013:965212.
• [2]Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS: Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat 2013, 45:15-21.
• [3]Verkooijen HM, Fioretta G, Pache JC, Franceschi S, Raymond L, Schubert H, Bouchardy C: Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes Control 2003, 14:13-17.
• [4]Peterson E, De P, Nuttall R: BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS One 2012, 7:e29177.
• [5]Navarro Silvera SA, Miller AB, Rohan TE: Risk factors for thyroid cancer: a prospective cohort study. Int J Cancer 2005, 116:433-438.
• [6]Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H: Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008, 93:809-814.
• [7]Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006, 91:4295-4301.
• [8]Yeh NC, Chou CW, Weng SF, Yang CY, Yen FC, Lee SY, Wang JJ, Tien KJ: Hyperthyroidism and thyroid cancer risk: a population-based cohort study. Exp Clin Endocrinol Diabetes 2013, 121:402-406.
• [9]Kim ES, Lim DJ, Baek KH, Lee JM, Kim MK, Kwon HS, Song KH, Kang MI, Cha BY, Lee KW, Son HY: Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 2010, 20:885-891.
• [10]Moeller LC, Führer D: Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer 2013, 20:R19-R29.
• [11]Sherman SI: Thyroid carcinoma. Lancet 2003, 361:501-511.
• [12]Kitahara CM, Linet MS, Beane Freeman LE, Check DP, Church TR, Park Y, Purdue MP, Schairer C, Berrington de González A: Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control 2012, 23:1615-1624.
• [13]Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, Schairer C, Schatzkin A, Shikany JM, Berrington de González A: Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011, 20:464-472.
• [14]Agudo A, Sala N, Pera G, Capellá G, Berenguer A, García N, Palli D, Boeing H, Del Giudice G, Saieva C, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Stenling R, Hallmans G, Martínez C, Bilbao R, Barricarte A, Navarro C, Quirós JR, Allen N, Key T, Bingham S, Khaw KT, Linseisen J, Nagel G, et al.: Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006, 15:2427-2434.
• [15]Kim HK, Yoon JH, Kim SJ, Cho JS, Kweon SS, Kang HC: Higher TSH level is a risk factor for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2013, 78:472-477.
• [16]Fiore E, Vitti P: Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012, 97:1134-1145.
• [17]Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, Belfiore A: Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab 2013, 98:1014-1021.
• [18]Morshed SA, Latif R, Davies TF: Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 2009, 150:519-529.
• [19]Hrafnkelsson J, Tulinius H, Kjeld M, Sigvaldason H, Jónasson JG: Serum thyroglobulin as a risk factor for thyroid carcinoma. Acta Oncol 2000, 39:973-977.
• [20]Shivaraj G, Prakash BD, Sonal V, Shruthi K, Vinayak H, Avinash M: Thyroid function tests: a review. Eur Rev Med Pharmacol Sci 2009, 13:341-349.
• [21]Park do J, Lim JA, Kim TH, Choi HS, Ahn HY, Lee EK, Kim KW, Park YJ, Yi KH, Cho BY: Serum thyroglobulin level measured after thyroxine withdrawal is useful to predict further recurrence in whole body scan-negative papillary thyroid cancer patients after reoperation. Endocr J 2012, 59:1021-1030.
• [22]Zhang L, Li H, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y: The clinical features of papillary thyroid cancer in Hashimoto’s thyroiditis patients from an area with a high prevalence of Hashimoto’s disease. BMC Cancer 2012, 12:610. BioMed Central Full Text
• [23]Kim KW, Park YJ, Kim EH, Park SY, Park DJ, Ahn SH, Park do J, Jang HC, Cho BY: Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto’s thyroiditis. Head Neck 2011, 33:691-695.
• [24]Azizi G, Malchoff CD: Autoimmune thyroid disease: a risk factor for thyroid cancer. Endocr Pract 2011, 17:201-209.
• [25]Fiore E, Rago T, Scutari M, Ugolini C, Proietti A, Di Coscio G, Provenzale MA, Berti P, Grasso L, Mariotti S, Pinchera A, Vitti P: Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases. J Endocrinol Invest 2009, 32:344-351.
• [26]Antonelli A, Mosca M, Fallahi P, Neri R, Ferrari SM, D’Ascanio A, Ghiri E, Carli L, Miccoli P, Bombardieri S: Thyroid cancer in systemic lupus erythematosus: a case–control study. J Clin Endocrinol Metab 2010, 95:314-318.
• [27]Yoshida H, Amino N, Yagawa K, Uemura K, Satoh M, Miyai K, Kumahara Y: Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases. J Clin Endocrinol Metab 1978, 46:859-862.
• [28]Feldt-Rasmussen U, Rasmussen AK: Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones 2010, 9:109-117.
• [29]Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
• [30]Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87:489-499.
• [31]Roberts DL, Dive C, Renehan AG: Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010, 61:301-316.
• [32]Mack WJ, Preston-Martin S, Dal Maso L, Galanti R, Xiang M, Franceschi S, Hallquist A, Jin F, Kolonel L, La Vecchia C, Levi F, Linos A, Lund E, McTiernan A, Mabuchi K, Negri E, Wingren G, Ron E: A pooled analysis of case–control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control 2003, 14:773-785.
• [33]Brand JS, Chan MF, Dowsett M, Folkerd E, Wareham NJ, Luben RN, van der Schouw YT, Khaw KT: Cigarette smoking and endogenous sex hormones in postmenopausal women. J Clin Endocrinol Metab 2011, 96:3184-3192.
• [34]Shiels MS, Rohrmann S, Menke A, Selvin E, Crespo CJ, Rifai N, Dobs A, Feinleib M, Guallar E, Platz EA: Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control 2009, 20:877-886.
• [35]Scott DA, Martin M: Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases. World J Gastroenterol 2006, 12:7451-7459.
• [36]Belin RM, Astor BC, Powe NR, Ladenson PW: Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004, 89:6077-6086.
• [37]Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Rasmussen LB: Smoking is negatively associated with the presence of thyroglobulin autoantibody and to a lesser degree with thyroid peroxidase autoantibody in serum: a population study. Eur J Endocrinol 2008, 158:367-373.